Healthcare Services Group Inc
Change company Symbol lookup
Select an option...
HCSG Healthcare Services Group Inc
IBB iShares Nasdaq Biotechnology ETF
NEP Nextera Energy Partners LP
FRAN Francesca's Holdings Corp
CDTI CDTi Advanced Materials Inc
UBER Uber Technologies Inc
MTX Minerals Technologies Inc
PRGS Progress Software Corp
CODA Coda Octopus Group Inc
WAB Westinghouse Air Brake Technologies Corp

Industrials : Commercial Services & Supplies | Small Cap Blend
Company profile

Healthcare Services Group, Inc. provides management, administrative and operating services to the housekeeping, laundry, linen, facility maintenance and dietary service departments of the healthcare industry, including nursing homes, retirement complexes, rehabilitation centers and hospitals located throughout the United States. The Company operates through two segments: housekeeping, laundry, linen and other services (Housekeeping), and dietary department services (Dietary). Its housekeeping service involves the management of a client's housekeeping department, which is responsible for the cleaning, disinfecting and sanitizing resident rooms and common areas of a client's facility. Its dietary services consist of managing the client's dietary department, which is responsible for food purchasing, meal preparation and providing professional dietitian services, including the development of menus that meet the dietary needs of residents.


Last Trade
0.0001 (0.00%)
B/A Size

Market Hours

Closing Price
Day's Change
1.31 (5.64%)
Bid close
Ask close
B/A Size
Day's High
Day's Low
(Heavy Day)

10-day average volume:

Conjunctivitis Treatment Market to Reach USD 4.38 Billion by 2027; Rapid Technological Advancements to Aid Growth: Fortune Business Insights(TM)

5:39 am ET August 26, 2020 (Globe Newswire) Print

The global conjunctivitis treatment market is set to gain traction from the rising technological advancements in the field of ophthalmology. Besides, the increasing discovery of new techniques of drug delivery would also impact the market positively. This information is given by Fortune Business Insights(TM) in a recently published report, titled, "Conjunctivitis Treatment Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Antibiotics, Antiviral, Anti-allergic, Artificial Tear and Others), By Disease Type (Bacterial Conjunctivitis, Viral Conjunctivitis, and Allergic Conjunctivitis) By Route of Administration (Topical, Oral, and Intravitreal), By Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies & Drug Stores), and Regional Forecast, 2020-2027."

The report further states that the conjunctivitis treatment market size was USD 3.85 billion in 2019 and is projected to reach USD 4.38 billion by 2027, exhibiting a CAGR of 3.7% during the forecast period.

Request a Sample Copy of the Research Report:

This Report Answers the Following Questions:

-- What are the market growth drivers, dynamics, and hindrances?

-- Which segment is set to lead the market in the near future?

-- Which company would generate the largest revenue?

-- How will the companies surge sales of new drugs for conjunctivitis treatment?

Drivers & Restraints-

Rising Awareness Programs about Eye-related Diseases will Propel Growth

Conjunctivitis can be of three types, namely, allergic, viral, and bacterial. The National Centre for Biotechnology Information mentioned that these types of diseases vary from person to person according to the season of the year and the patient's age. It also spreads rapidly through direct contact, such as sneezing, coughing, and hands. Also, numerous companies are trying to launch new drug formulations and innovative drug delivery systems for faster recovery of the patients. Apart from that, ocular disorder management and the increasing awareness programs about eye-related diseases would contribute to the conjunctivitis treatment market growth in the coming years.

The emergence of the COVID-19 pandemic has caused heavy losses for a large number of companies worldwide. It has disrupted the supply chain and halted production processes. Most of the healthcare companies are persistently striving to invent a vaccine to stop this deadly pandemic. Our report would provide authentic information about the current scenario of every market.

To get to know more about the short-term and long-term impact of COVID-19 on this market,

please visit:

COVID-19 to Contribute to a Lower Growth Due to Strong Decline in Hospital Visits

The outbreak of the COVID-19 pandemic across the globe is set to negatively impact the global market growth. Despite the patients suffering from conjunctivitis tend to be at a high risk of getting injected by viral conjunctiva that is usually caused because of adenovirus, the market is expected to undergo a decline. While coronavirus also causes several similar ocular signs and symptoms, such as conjunctivitis infection, watery discharge, photophobia, and eye irritation. Due to the stringent lockdowns imposed by governments across the globe, the postponement or cancellations of non-life-threatening medical visits is expected to restrict the market growth as lesser prescriptions for conjunctivitis will be issued in this time period.


Anti-allergic Segment to Lead Owing to Rising Usage to Treat Allergic Conjunctivitis

Based on drug class, the market is divided into artificial tears, anti-allergic, antiviral, antibiotics, and others. Out of these, the anti-allergic segment held 65.0% conjunctivitis treatment market share in 2019. This growth is attributable to their increasing usage in the treatment of allergic and also due to the new product launches. They help in reducing eye discomfort and infections. The anti-allergic segment is set to dominate throughout the forthcoming years backed by their high usage in treating allergic conjunctivitis.

Quick Buy - Conjunctivitis Treatment Market Research Report:

Regional Analysis-

North America to Dominate Fueled by Presence of Several Industry Giants

Geographically, North America procured USD 1.85 billion in terms of revenue in 2019 and is expected to lead in the near future. This growth is attributable to the rising awareness about eye diseases amongst the masses, presence of industry giants in the region, and the increasing cases of conjunctivitis. Europe is anticipated to remain in the second position on account of the surging usage of novel drugs for conjunctivitis treatment, rising pool of conjunctivitis patients, and increasing healthcare expenditure in this region.

Competitive Landscape-

Key Players Focus on Receiving Fast Track Approvals for Their New Drugs

The companies operating in the market are presently focusing on investing hefty amounts of money to conduct research and develop activities. These are helping them to develop new drugs for conjunctivitis treatment. They are also trying to receive approvals for their novel drugs from the regulatory bodies. Below are two of the latest industry developments:

-- April 2020: Ocular Therapeutix(TM), Inc., a biopharmaceutical firm declared the Phase 3 clinical trial results. It was conducted to find out the efficacy and safety of DEXTENZA(R) for the treatment of ocular itching caused by allergic conjunctivitis. As per the results, DEXTENZA is capable of treating the disease.

-- May 2017: The U.S. Food and Drug Administration (FDA) announced its approval of a New Drug Application (NDA) named Zerviate. It will be used to treat ocular itching that is caused by allergic conjunctivitis. It is considered to be the first topical ocular formulation of Nicox, an ophthalmology company based in France.

Fortune Business Insights(TM) lists out the names of all the manufacturers of drugs used for conjunctivitis treatment. They are as follows:

-- Allergan

-- Akorn, Incorporated

-- Eyevance Pharmaceuticals LLC.


-- Santen Pharmaceutical Co., Ltd

-- Alcon

-- Bausch & Lomb Incorporated

-- Others key market players

Have Any Query? Ask Our Experts:

Table of Contents:

-- Introduction

    -- Research Scope

    -- Research Scope

    -- Market Segmentation

    -- Research Methodology

    -- Definitions and Assumptions

    -- Executive Summary

    -- Market Dynamics

      -- Market Drivers

      -- Market Drivers

      -- Market Restraints

      -- Market Opportunities

      -- Key Insights

        -- Key Industry Developments (Mergers, Acquisitions, and Partnerships, etc.)

        -- Key Industry Developments (Mergers, Acquisitions, and Partnerships, etc.)

        -- Pipeline Analysis

        -- New Product Launches, Key Market Players

        -- Prevalence of Conjunctivitis, by key Countries/region

        -- COVID-19 Impact on Global Conjunctivitis Treatment Market

        -- Global Conjunctivitis Treatment Market Analysis, Insights and Forecast, 2016-2027

          -- Key Findings / Summary

          -- Key Findings / Summary

          -- Market Analysis, Insights and Forecast - By Drug Class

            -- Antibiotics

            -- Antibiotics

            -- Antiviral

            -- Anti-allergic

            -- Artificial Tears

            -- Others

            -- Market Analysis, Insights and Forecast - By Disease Type

              -- Bacterial Conjunctivitis

              -- Bacterial Conjunctivitis

              -- Viral Conjunctivitis

              -- Allergic Conjunctivitis

              -- Market Analysis, Insights and Forecast - By Route of Administration

                -- Topical

                -- Topical

                -- Oral

                -- Market Analysis, Insights and Forecast - By Distribution Channel

                  -- Hospital Pharmacies

                  -- Hospital Pharmacies

                  -- Online Pharmacies

                  -- Retail Pharmacies & Drug Stores

                  -- Market Analysis, Insights and Forecast - By Region

                    -- North America

                    -- North America

                    -- Europe

                    -- Asia Pacific

                    -- Latin America

                    -- Middle East & Africa

                    TOC Continued....!

                    Get your Customized Research Report:

                    Have a Look at Related Reports:

                    Orphan Drugs Market Size, Share & COVID-19 Impact Analysis, By Therapy Area (Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy, and Others), By Drug Type (Biologics, and Non-Biologics), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Sales, and Others), and Regional Forecast, 2020-2027

                    Diabetes Drugs MarketSize, Share and Industry Analysis By Drug Class (Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors), Diabetes Type (Type 1, Type 2), Route of Administration (Oral, Subcutaneous, Intravenous), Distribution Channel (Online pharmacies, Hospital Pharmacies, Retail Pharmacies) & Regional Forecast 2019 - 2026

                    Antiviral Drugs MarketSize, Share & Industry Analysis, By Drug Class (Protease Inhibitors, Polymerase Inhibitors, Integrase Inhibitors, Combination Drugs, Reverse Transcriptase Inhibitors, and Others), By Disease Indication (Hepatitis, Human Immunodeficiency Virus (HIV), Influenza, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Channel) and Regional Forecast, 2019-2026

                    Pediatric Drugs and Vaccines Market Size, Share and Global Trend By Product (Vaccines, Drugs) By Disease Indication (Infectious Disease, Cancer, Allergy And Respiratory, Nervous System Disorders, Cardiovascular Disease, Diabetes, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and Geography Forecast till 2026

                    Hemophilia Drugs MarketSize, Share and Industry Analysis By Disease Indication (Hemophilia A, B & C), By Therapy Type (Recombinant Therapy, Plasma Therapy & Others), By Distribution Channels (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), and Regional Forecast 2018-2025

                    Antiepileptic Drugs Market Size, Share & Industry Analysis, By Drug Generation (First Generation, Second Generation, and Third Generation), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2019-2026

                    About Us:

                    Fortune Business Insights(TM) offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.

                    Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.

                    At Fortune Business Insights(TM) we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.

                    Contact Us:

                    Fortune Business Insights(TM) Pvt. Ltd.

                    308, Supreme Headquarters,

                    Survey No. 36, Baner,

                    Pune-Bangalore Highway,

                    Pune - 411045, Maharashtra, India.


                    US :+1 424 253 0390

                    UK : +44 2071 939123

                    APAC : +91 744 740 1245


                    Fortune Business Insights(TM)

                    LinkedIn | Twitter | Blogs

                    Press Release:


                    comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.